ALT

Healthcare Biotechnology

Altimmune, Inc.

$2.67

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

519.36M

Avg Volume

4.19M

EPS

-$0.76

52W High

$6.44

52W Low

$2.56

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-4.00

P/B Ratio

1.10

P/S Ratio

16753.62

EV/EBITDA

-2.32

EV/Revenue

7390.36

PEG Ratio

32.62

Margins

Gross Margin 0.0%

Operating Margin (318493.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(28.9%)

Return on Assets

(17.2%)

Liquidity & Leverage

Current Ratio

26.78

Quick Ratio

26.37

Debt / Equity

0.08

Total Cash

326.28M

Total Debt

36.02M

About

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

altimmune.com